Oral retinoids and pregnancy
- 1 August 1996
- journal article
- research article
- Published by AMPCo in The Medical Journal of Australia
- Vol. 165 (3) , 164-167
- https://doi.org/10.5694/j.1326-5377.1996.tb124895.x
Abstract
The oral retinoids isotretinoin and etretinate are uniquely effective in the treatment of severe cystic acne and keratinisation disorders. Because of their known teratogenicity, there are strict prescription guidelines, but exposure during pregnancy still occurs. A dedicated effort by women and their clinicians is required, involving patient selection, education and informed consent, detailed contraceptive counselling, and careful monitoring and management, including pregnancy testing before commencement of therapy.Keywords
This publication has 19 references indexed in Scilit:
- Terminations of Pregnancy for Exposure to Oral Retinoids in South Australia, 1985–1993Australian and New Zealand Journal of Obstetrics and Gynaecology, 1995
- A Pregnancy-Prevention Program in Women of Childbearing Age Receiving IsotretinoinNew England Journal of Medicine, 1995
- Side effects of systemic retinoids and their clinical managementJournal of the American Academy of Dermatology, 1992
- Epidemiology of isotretinoin exposure during pregnancyJournal of the American Academy of Dermatology, 1992
- Retinoid therapy—a real hazard for the developing embryoBJOG: An International Journal of Obstetrics and Gynaecology, 1992
- Patterns of Prescribing Isotretinoin: Focus on Women of Childbearing PotentialAnnals of Pharmacotherapy, 1992
- Recommendations for isotretinoin use in women of childbearing potentialTeratology, 1991
- SURVEY OF AUSTRALIAN ISOTRETINOIN PRESCRIBINGAustralasian Journal of Dermatology, 1991
- Vitamin A congenersTeratology, 1986
- Retinoic Acid EmbryopathyNew England Journal of Medicine, 1985